Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, not at all what I'm saying. I'm just pointing out that the competition is fierce, and many promising therapies are well ahead. The market can only accommodate so many.
I agree with this completely. In fact, I'm in ENZC for the potential of their HIV therapy. If their COVID treatment comes to fruition, it's icing on the cake.
BUT - there are dozens of therapies already in P2/3 clinical trials showing great promise, along with existing drugs being repurposed to treat COVID patients. RLF-100, Bucillamine, numerous arthritis drugs, and a range of other anti-iflammatories.
Here's a snap shot of just SOME of the COVID vaccines running trials:
https://newsinteractives.cbc.ca/coronavirusvaccinetracker/
And here is a list of therapeutics in development and/or trials to treat patients:
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker
Monoclonal antibodies are not the only game in town, not by a mile, for the treatment of COVID.
Agreed, it was reassuring to see the update. A few weeks isn't a huge deal. Fingers crossed that they publish the 10K soon.
Excellent, as always.
Was there an additional PR besides this one? I don't see any mention of retiring of shares:
PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial funding received on October 26, 2020. The full text of the update is presented below.
November 13, 2020
Dear Investors and Supporters,
We are making great progress on our plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus. On December 1, we are expanding our lab to the campus of Texas A&M University at its Institute for Preclinical Studies. This expansion will allow us to complete production of monoclonal antibodies against both the HIV virus and the CoronaVirus and collaborate with the biopharma experts on the campus. Although we have NIH grant applications pending for the production of anti-HIV and anti-CoronaVirus monoclonal antibodies, we have secured funding that allows us to proceed without delay.
We welcome the recent news from Eli Lilly regarding its production of monoclonal antibodies for treatment of COVID-19 patients. We note that experts agree that for a monoclonal antibody therapy to be effective, a "combination" (or "cocktail") of such antibodies used in combination will likely be needed. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that a success in treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies - meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms.
Thus, we recognize that while other pharma companies may produce effective antibodies, there will necessarily be a need for additional monoclonal antibodies to be used in tantum with those initially discovered. Also, and unfortunately, the mutation of viruses, both the HIV and the CoronaVirus, will necessitate the production of numerous effective antibodies as the virus mutates around the therapeutics initially discovered.
Here is why we are confident in our technology.
It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as "virus escape". Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.
Thus, while the Eli Lilly monoclonal antibody will hopefully have lasting effect, if it is targeting a mutable site on the virus, the virus may "escape" around it. And indeed, a close look at the results of the Eli Lilly initial tests of its antibody show that the antibody reduced the effect of the virus in some but not all of the patients receiving the antibody.
Thus, even these initial Eli Lilly trials demonstrate that additional monoclonal antibodies can be expected to be needed to fully treat COVID-19 patients.
The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus Proteins.
In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".
Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
We are actively moving forward in our production and testing of such antibodies.
Sincerely,
Charles S. Cotropia
CEO
BioClonetics Immunotherapeutics, Inc.
The recent appointment of Dr. Ronald Moss to the medical advisory board is another step toward achieving a successful combination of the management and technology teams and business strategies of the two entities. The second tranche of the initial funding is scheduled for receipt early next week and those funds will be used to further our clinical and administrative progress. Final documentation of the combination agreement is currently being reviewed with closing anticipated to be before the end of the month.
About Enzolytics, Inc;
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind. Enzolytics is a 49% shareholder of IMMB BG.
Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
About BioClonetics Immunotherapeutics, Inc.
BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the CoronaVirus.
For an implantable device, I'm thinking GE Healthcare, Boston Scientific, or Medtronic would be likelier targets.
Cerebain Biotech Announces General Business Update
7:28 am ET November 12, 2020 (BusinessWire)
Cerebain Biotech Corp. (OTC: CBBT), (the "Company" or "Cerebain") today announces a General Business Update.
Cerebain is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company's SEC filings current.
Upon the completion of the acquisition, Cerebain will initiate a review of its overall business and corporate strategic plan. The corporate strategic initiatives to be developed and implemented include, but are not limited to, rebranding and repositioning of the Company's overall business plan and a comprehensive growth strategy focused on revenue generation through a comprehensive roll-up acquisition strategy of target qualified candidates in select industries.
About Cerebain Biotech Corp.
Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer's disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
About PKG Inc.
PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps to raise your company to the next level by leveraging our skills in engineering and technology integration across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all their product development and manufacturing needs. In addition to our expertise of system level devices and human machine interfaces, PKG also offers incubation and acceleration services for startup business and entrepreneurs.
Thanks Merrill. Did Alan provide any insight into what led to the delay, beyond under estimating time required? Any word about what the document which led to the delay is all about?
Amen to that.
And what is this one document? Is it the 10K? The secret ingredients to Coke?
I'm just struggling to think of a document, needing to be produced by either Cerebain or PKG, which could hold up the acquisition.
Can you post the e-mail here? I don't see any mention of this on their website.
That could be so, but why would PKG play along with it, even to go so far as to post the announcement on their website and social media? What does PKG have to gain by maintaining a ruse? Or, how is it that PKG got duped?
Quite possibly. But all we have at this time, are patents; at least to the knowledge of anyone on this board. If I'm not mistaken, the assumption re: the PKG acquisition is that they are capable of producing a workable prototype for use in clinical trials.
He says right in there:
This is a great nation.
And we are a good people.
This is the United States of America.
I think the point is simply that, as we always have, we will continue to strive to improve, to do better, to increase equality of opportunity.
Also, it was a victory speech, which by their nature, are generally about hope and inspiration. I wouldn't read too deeply into it.
Context:
You see, I believe in the possibility of this country.
We’re always looking ahead.
Ahead to an America that’s freer and more just.
Ahead to an America that creates jobs with dignity and respect.
Ahead to an America that cures disease — like cancer and Alzheimers.
Ahead to an America that never leaves anyone behind.
Ahead to an America that never gives up, never gives in.
This is a great nation.
And we are a good people.
This is the United States of America.
news.google.com/articles/CAIiEHJ59TCNcFIewtyPIAdhw9AqGQgEKhAIACoHCAowvIaCCzDnxf4CMP2F8gU?hl=en-US&gl=US&ceid=US%3Aen
To be fair, I've been an investor in PLUG (Plug Power) since 2000! It's been a LOOOONNNNNGGGGG winding road, with a helluva lot of bumps along the way. But I'll be damned if it hasn't been worth the wait.
Sometimes you've got to be patient. Two years, to me, doesn't seem like much. But, I do get antsy when projections and dates fall through.
I respect and understand your concern of this being a P&D, but the fact the PKG has also issued press releases, and posts on their social media, about the merger, gives me hope. Why would they risk their reputation?
Just realized that Cerebain has been working with NMS Consulting since at least 2018. On one hand, what the hell has been taking so long. On the other, I suppose at this point, NMS is intimately familiar with Cerebain, which should help expedite, and bring this acquisition to fruition.
https://www.businesswire.com/news/home/20181204005563/en/Cerebain-Initiates-Repositioning-and-Review-of-Business-and-Corporate-Strategic-Growth-Plan
December 04, 2018 08:30 AM Eastern Standard Time
COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC:CBBT), (the “Company” or “Cerebain”) today announced that it has initiated a repositioning and review of its overall business and corporate strategic plan to maximize shareholder value. The corporate strategic initiatives to be developed and implemented include, but are not limited to, a potential sale or divestiture of certain Company assets, rebranding and repositioning of the Company’s overall business plan and a comprehensive growth strategy focused on revenue generation through a comprehensive roll-up acquisition strategy of target qualified candidates in select industries. As part of the overall plan, Cerebain shall continue to pursue value-enhancing initiatives as a standalone company and a capital structure optimization policy that may involve potential financings or partnerships. To assist and advise on the development and implementation of the Company’s overall plan, it has engaged NMS Consulting, Inc., (“NMS Consulting”) an independent, global focused management consulting, corporate strategy and strategic communications firm.
In addition to a review of Cerebain’s business and corporate strategic initiatives, NMS Consulting will also advise Cerebain on a corporate restructuring and cost savings plan, under which it will identify opportunities to optimize operations, drive efficiency and reduce costs.
Yep, what's up there is old, but I'm waiting for the late filings to be posted. Fingers crossed for that to happen by the end of next week.
I've got repetitive refresh disorder from CBBT!
https://www.otcmarkets.com/stock/CBBT/disclosure
Today marks two weeks. Hopefully we see the 10K filed today or tomorrow. But, given the craziness in this world, I won't be shocked if it doesn't happen for another week or two.
BUT - if not the 10K filing, I do hope for some other indicators of progress.
Got it, thanks again.
Thank you, much appreciated. So really, more of a formality than anything else? Is that also when we should expect the 'Q' to be removed from the ticker?
Rule 3022. Final Decree in Chapter 11 Reorganization Case
Primary tabs
After an estate is fully administered in a chapter 11 reorganization case, the court, on its own motion or on motion of a party in interest, shall enter a final decree closing the case.
Notes
(As amended Mar. 30, 1987, eff. Aug. 1, 1987; Apr. 30, 1991, eff. Aug. 1, 1991.)
Notes of Advisory Committee on Rules—1983
Section 350 of the Code requires the court to close the case after the estate is fully administered and the trustee has been discharged. Section 1143 places a five year limitation on the surrender of securities when required for participation under a plan but this provision should not delay entry of the final decree.
Notes of Advisory Committee on Rules—1991 Amendment
Entry of a final decree closing a chapter 11 case should not be delayed solely because the payments required by the plan have not been completed. Factors that the court should consider in determining whether the estate has been fully administered include (1) whether the order confirming the plan has become final, (2) whether deposits required by the plan have been distributed, (3) whether the property proposed by the plan to be transferred has been transferred, (4) whether the debtor or the successor of the debtor under the plan has assumed the business or the management of the property dealt with by the plan, (5) whether payments under the plan have commenced, and (6) whether all motions, contested matters, and adversary proceedings have been finally resolved.
The court should not keep the case open only because of the possibility that the court's jurisdiction may be invoked in the future. A final decree closing the case after the estate is fully administered does not deprive the court of jurisdiction to enforce or interpret its own orders and does not prevent the court from reopening the case for cause pursuant to §350(b) of the Code. For example, on motion of a party in interest, the court may reopen the case to revoke an order of confirmation procured by fraud under §1144 of the Code. If the plan or confirmation order provides that the case shall remain open until a certain date or event because of the likelihood that the court's jurisdiction may be required for specific purposes prior thereto, the case should remain open until that date or event.
So what is this final decree due in January all about???
Order Confirming Chapter 11 Plan. Final Decree due by 1/28/2021. Signed on 10/30/2020 (jaf)
https://www.pacermonitor.com/public/case/33077659/BioRestorative_Therapies,_Inc
Cerebain should really update their website, both content (including press releases), but also aesthetically. Understood that it's trivial in comparison to the acquisition, but still, their website is their public face to the world.
Looking at the PRs posted to their site, the last one was from 2017:
http://www.cerebain.com/cerebain-biotech-engages-nms-capital-advisors/
NMS Consulting was spun off from NMS Capital Advisors last year. I suppose it's a good sign that they have a multi year relationship with the NMS family of companies, perhaps will allow for a smoother transition as they ought to already be intimately familiar with Cerebain.
Yep, 100% agree with you on that. And given the COVID world we live in, and the resultant disruptions to schedules and business, it's best to take the mindset of under promising, and hoping for them to over deliver.
Your DD is much appreciated. That said, I always inflate these estimates by 50% - 100%. If the filing hits next week, I too will be dancing naked on the roof. But I suspect it'll be closer to the week prior Thanksgiving.
Beautiful. Now if we could just get an update; from Cerebain, from PKG, or even from NMS Consulting. Even better, some SEC filings.
That's true, but device trials still take months to years.
Can you share the info on the existing device results? I seem to recall that that was from observations during surgery over a decade ago, in which the omentum has been stimulated and led to temporary gains in mental acuity, which is what led to Cerebain developing patents for the device - not that a device had been created.
I look forward to that as much as anyone else, but to our knowledge, device development hasn't even started, let alone clinical trials - which can take years.
Yeah, not what I want to wake up to. But, even the gap down is well ahead of where it opened yesterday.
NMS Consulting Named One of 50 Fastest Growing Companies of 2019 by The Silicon Review
https://www.accesswire.com/550540/NMS-Consulting-Named-One-of-50-Fastest-Growing-Companies-of-2019-by-The-Silicon-Review
BEVERLY HILLS, CA / ACCESSWIRE / July 1, 2019 / NMS Consulting, Inc. ("NMSC"), a global strategic advisory firm, has been named one of the 50 Fastest Growing Companies of 2019 by The Silicon Review, a leading Business and Technology magazine.
Founded in 2018 resulting from the uplifting and spinoff of the global consulting practice of a leading private equity and advisory firm, NMS Consulting was formed to serve as an independent, global focused management consulting, corporate advisory and strategic communications firm.
NMSC's Managing Partner, Trevor M. Saliba commented "NMS Consulting was formed to be more than just a consulting firm to our clients, but to strive to be a dedicated catalyst to their growth and success. By targeting an underserved market, we have experienced significant growth of new clients and staff to our global platform."
NMSC strives to offer customized consulting solutions for small to medium-sized companies rooted in our global team's ability to deliver the expertise of much larger consulting conglomerates, but with the personalized approach, flexibility and affordable cost often associated with a boutique firm. NMSC is quickly approaching a professional global team of approximately 100 consultants from various industry backgrounds across seven global locations, many who have worked for prominent consulting firms such as Capgemini, Accenture, McKinsey & Company, and Bain & Company.
The Silicon Review is a leading business and technology print and online publication, with a community of writers that include CEOs, CIOs, CXOs, CTOs, IT VPs and other executives along nine verticals. The 2019 50 Fastest Growing Companies list identifies companies making strides in the fields of business and technology.
About NMS Consulting
NMS Consulting is a global strategic advisory firm focused on delivering client solutions across three business units: management consulting, corporate advisory and strategic communications. The firm provides strategic counsel to private and public companies, governments, philanthropic organizations and the individuals who lead them. For more information, please visit www.nmsconsulting.com.
Media Contact:
Terrie Gorman
+1.310.855.0020
info@nmsconsulting.com
NMS Consulting is legit. This isn't some three person frat-boy operation working out of a strip mall store front. That is to say, NMS' presence only adds legitimacy and confidence to the PKG acquisition.
https://www.linkedin.com/company/nms-consulting-inc/ (if you have a LinkedIn account, you will see that they shared news of the Cerebain/PKG deal on their page).
https://nmsconsulting.com
https://thesiliconreview.com/magazine/profile/nms-provides-strategic-counsel-to-organizations-and-the-individuals-who-lead-them
https://www.consulting.us/news/4545/nms-consulting-expands-its-footprint-in-europe
https://www.consultancy.in/news/3334/indian-market-entry-consultancy-cibc-partners-with-nms
https://www.consulting.us/news/4581/nms-adds-senior-advisors-in-beverly-hills-and-orange-county
DECN Announces Commencement of US-Based Donor Study for FDA EUA Guidance Testing for Their 10.5 Second Genviro! Saliva Swift COVID-19 Test Kits
https://finance.yahoo.com/news/decn-announces-commencement-us-based-131500742.html?.tsrc=fin-srch
Donor Study Activities Began, Friday October 16th at FDA and CLIA Certified Testing Lab; Data to Also Be Used for EU CE Mark and for Emergency Approval in the Russian Federation Countries
LOS ANGELES, CA / ACCESSWIRE / October 19, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., today announced it will begin its donor study as a precursor for its FDA EUA, EU CE Mark and Russian Federation testing of its Genviro! Saliva Swift Kit for the detection of Covid-19. The donor study, and eventual FDA guideline testing, will be conducted by the company's FDA and CLIA certified testing partner in the US.
"Our plans are on target for fourth quarter FDA EUA, EU CE Mark and Russian Federation submissions. The donor study is the launching pad for the work that needs to be done and early work is both encouraging and exceeding our expectations," said CEO Keith Berman.
"When the current rounds of testing are completed, will have had three series of tests from which we expect to hopefully obtain FDA authorization and to enable the U.S. professionals to be confident that GenViro! Swift results are as accurate as possible. EU CE Mark and Russian Federation applications, although both in similar emergency filing class as the FDA guidelines, follow a different, less stringent and hopefully quicker path to approval. We are further emboldened by the recent attention to the value and efficacy of saliva testing as both accurate and rapid, which is exactly what we have always sought from the Genviro! Saliva Swift Kit."
GenViro! Swift Kits are not yet approved for sale or distribution in the USA or Puerto Rico.
While the company's initial FDA EUA submission back in April involved its blood finger prick version of the GenViro! Swift kit, further advances brought it to the current saliva methodology that is both less invasive and according to recent studies is expected to be more accurate.
https://time.com/5891887/covid-19-saliva-spit-test/
NMS Consulting is legit. This isn't some three person frat-boy operation working out of a strip mall store front. That is to say, NMS' presence only adds legitimacy and confidence to the PKG acquisition.
https://www.linkedin.com/company/nms-consulting-inc/ (if you have a LinkedIn account, you will see that they shared news of the Cerebain/PKG deal on their page).
https://nmsconsulting.com
https://thesiliconreview.com/magazine/profile/nms-provides-strategic-counsel-to-organizations-and-the-individuals-who-lead-them
https://www.consulting.us/news/4545/nms-consulting-expands-its-footprint-in-europe
https://www.consultancy.in/news/3334/indian-market-entry-consultancy-cibc-partners-with-nms
https://www.consulting.us/news/4581/nms-adds-senior-advisors-in-beverly-hills-and-orange-county
Excellent news.
I wish Cerebain would claim their LinkedIn page and start sharing the news there as well. LinkedIn offers a far better chance of their updates being viewed by potential investors, partners, etc. than Twitter or Facebook.
They're a burgeoning biotech pioneer, not Nicki Manaj lol
Great game, btw (your name!). I can still hear the music in my head 35 years after first playing it.